Abiraterone and Intermediates
Abiraterone is a targeted cytochrome CYP17 (17) α- Hydroxylase / c17,20-lyase) inhibitor produces abiraterone after hydrolysis. Abiraterone acetate inhibits cytochrome CYP17 through chemicalbook, thereby reducing the production of testosterone. It is suitable for the treatment of patients with castrated refractory prostate cancer (CRPC) who have received previous chemotherapy containing docetaxel.
Abiraterone is an oral inhibitor of cytochrome oxidase P450 (CYP450) C17. It reduces androgen levels by inhibiting cyp450c17, a key enzyme in androgen synthesis, and inhibits androgens in testis and other parts of the body.
Abiraterone is only approved for the treatment of paclitaxel chemotherapy refractory CPRC